LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Emergent BioSolutions Inc

Fermé

SecteurSoins de santé

5.65 -3.09

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.61

Max

5.93

Chiffres clés

By Trading Economics

Revenu

-146M

-31M

Ventes

-105M

189M

BPA

0.71

Marge bénéficiaire

-16.535

Employés

900

EBITDA

-164M

13M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+129.59% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-223M

317M

Ouverture précédente

8.74

Clôture précédente

5.65

Sentiment de l'Actualité

By Acuity

34%

66%

97 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Emergent BioSolutions Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 mai 2025, 23:40 UTC

Actions en Tendance

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 mai 2025, 23:33 UTC

Principaux Mouvements du Marché

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 mai 2025, 23:25 UTC

Principaux Mouvements du Marché

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 mai 2025, 23:25 UTC

Résultats

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mai 2025, 22:58 UTC

Résultats

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 mai 2025, 21:35 UTC

Résultats

Cisco Systems Names Patterson as CFO, Patel as President

14 mai 2025, 23:59 UTC

Market Talk

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 mai 2025, 23:49 UTC

Market Talk

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 mai 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

14 mai 2025, 23:48 UTC

Market Talk

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 mai 2025, 23:47 UTC

Market Talk

Gold Gains on Possible Technical Recovery -- Market Talk

14 mai 2025, 23:34 UTC

Acquisitions, Fusions, Rachats

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 mai 2025, 23:10 UTC

Résultats

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 mai 2025, 23:07 UTC

Résultats

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 mai 2025, 23:00 UTC

Actualités

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 mai 2025, 22:43 UTC

Résultats

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 mai 2025, 22:34 UTC

Résultats

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 mai 2025, 22:33 UTC

Résultats

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero Did Not Declare a Dividend>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 mai 2025, 22:30 UTC

Résultats

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 mai 2025, 22:28 UTC

Résultats

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 mai 2025, 22:28 UTC

Résultats

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 mai 2025, 22:27 UTC

Résultats

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 mai 2025, 22:27 UTC

Résultats

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 mai 2025, 22:23 UTC

Actualités

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 mai 2025, 22:15 UTC

Résultats

Correction to Cisco Earnings Article -- WSJ

14 mai 2025, 21:48 UTC

Résultats

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 mai 2025, 21:37 UTC

Résultats

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparaison

Variation de prix

Emergent BioSolutions Inc prévision

Objectif de Prix

By TipRanks

129.59% hausse

Prévisions sur 12 Mois

Moyen 13.5 USD  129.59%

Haut 15 USD

Bas 12 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

4.95 / N/ASupport & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

97 / 382Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.